Related references
Note: Only part of the references are listed.Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy
J. S. Orange et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2012)
Subcutaneous Hizentra® (20%) Is Better Tolerated And Shares Similar Efficacy Compared To Subcutaneous Vivaglobin® (16%)
D. Nguyen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Home-Based Subcutaneous Immunoglobulin Versus Hospital-Based Intravenous Immunoglobulin in Treatment of Primary Antibody Deficiencies: Systematic Review and Meta Analysis
Hassan Abolhassani et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial
Brinda Emu et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies
Melvin Berger et al.
CLINICAL IMMUNOLOGY (2011)
Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy
S. Jolles et al.
CLINICAL IMMUNOLOGY (2011)
Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency
Richard L. Wasserman et al.
CLINICAL PHARMACOKINETICS (2011)
Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease
Richard L. Wasserman et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Incidence of Infection is Inversely Related to Steady-State (Trough) Serum IgG Level in Studies of Subcutaneous IgG in PIDD
Melvin Berger
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease
R. L. Wasserman et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies
Jordan S. Orange et al.
CLINICAL IMMUNOLOGY (2010)
Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years
Mary Lucas et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Immunoglobulin Dosage and Switch from Intravenous to Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Hypogammaglobulinemia: Decreasing Dosage Does Not Alter Serum IgG Levels
Sylvain Thepot et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
John B. Hagan et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Immunomodulatory Therapy to Achieve Maximum Efficacy: Doses, Monitoring, Compliance, and Self-infusion at Home
Mary Lucas et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously
Shilpa H. Desai et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous Routes
Francisco A. Bonilla
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2008)
Biologic IgG level in primary immunodeficiency disease: The IgG level that protects against recurrent infection
Vincent R. Bonagura et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases
Hans D. Ochs et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2006)
Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies -: A prospective, multi-national study
Ann Gardulf et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2006)
Clinical pharmacokinetics of etanercept: A fully humanized soluble recombinant tumor necrosis factor receptor fusion protein
HH Zhou
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Share Paper
